Azoniaspiro(3-Alpha-Benziloyloxy-Nortropan-8,1'-Pyrrolidine)-Chloride

How Crystalline Habit Modulates Dissolution in Immediate-Release Solid Dosage Forms Produced via Direct Compression

In the manufacture of immediate-release tablets containing azoniaspiro(3-alpha-benziloyloxy-nortropan-8,1'-pyrrolidine)-chloride, the particle engineering strategy upstream of blending exerts a disproportionate influence on disintegration kinetics. The monohydrate form is preferred over the anhydrous lattice due to its reduced hygroscopicity; however, micronization through a spiral jet mill operating at a grinding pressure of 3.5 bar to 4.0 bar with a Venturi feed pressure of 4.5 bar often induces localized amorphization on crystal surfaces. This mechanically activated amorphous layer, confirmed by dynamic vapor sorption isotherms exhibiting a recrystallization event at 55% RH, accelerates moisture uptake during wet granulation and is therefore incompatible with that process route. The industry compliance framework mandates conformance to USP <711> Dissolution and <905> Uniformity of Dosage Units, with the European Pharmacopoeia (Ph. Eur.) 10.8 monograph setting acceptance criteria for related substances at NLT 99.0% purity by HPLC. The formulation scale is anchored to a 20 mg unit dose, where the active constitutes between 12.5% w/w and 15.0% w/w of a 160 mg core tablet weight, directly compressed on a rotary tablet press equipped with multi-tip tooling. The balance consists of spray-dried lactose monohydrate (Dilactose S, serving as a brittle filler to compensate for the plasticity of microcrystalline cellulose PH-102), sodium starch glycolate (Explotab) at 4.0% w/w for intra-granular wicking, and a final lubrication step with magnesium stearate of vegetable origin, screened through a 500 μm mesh and blended for exactly 3 minutes at 25 rpm in a bin blender. Extended lubrication beyond 5 minutes causes a hydrophobic film to coat the API particles, depressed dissolution profiles, and a drop in breaking force due to excessive coverage of binder sites. The terminal product is a white-to-off-white, round, biconvex, film-coated tablet, debossed with a logo on one face and a break score on the reverse, identified by the therapeutic category of muscarinic receptor antagonists for overactive bladder.

Processing Window Vulnerabilities During High-Shear Wet Granulation of a Quinuclidinyl Benzilate Salt

Azoniaspiro(3-alpha-benziloyloxy-nortropan-8,1'-pyrrolidine)-chloride exhibits a pronounced susceptibility to hydrolytic degradation of the ester linkage connecting the benzilic acid moiety to the nortropane scaffold when exposed to aqueous granulation fluids above 40°C. The process design therefore imposes a strict critical quality attribute (CQA) boundary: granulation end-point must be achieved within a product temperature range of 28°C to 32°C, monitored continuously via an infrared sensor embedded in the lid of a top-driven high-shear mixer with a working capacity of 600 L. The binder solution, typically pregelatinized starch at 5.0% w/w concentration in purified water, is chilled to 8°C before being metered through a peristaltic pump at an addition rate of 0.8 kg/min. This slow incorporation is critical: adding the binder bolus raises local moisture content instantly and initiates acid-catalyzed ester cleavage, generating benzilic acid and azoniaspiro-alcohol as primary degradants tracked under the ICH Q3B(R2) qualification threshold of 0.2% for unspecified impurities. Following wet massing, the granules are de-lumped through a conical mill fitted with a rasp screen, and drying proceeds in a fluid bed dryer with an inlet air temperature of 55°C and a dew point of -20°C, achieving a loss-on-drying endpoint of 2.0% to 2.8%. Regulatory adherence requires validation against ICH Q1A(R2) stability protocols in both Alu-Alu and PVC/PVDC blisters, with dissolution testing in 0.1 N HCl (pH 1.2) using USP Apparatus II at 50 rpm. The compliant terminal dosage unit is a hard gelatin capsule of size 2, containing 20 mg of active ingredient blended with talc and a hydrophobic flow agent such as glyceryl dibehenate, locked inside a two-piece opaque capsule shell to shield the hygroscopic granular fill from uncontrolled atmospheric moisture.

Technical Inquiry: Can Controlled Porosity Osmotic Pumps Overcome the First-Pass Metabolism Liability?

The clinical objective of delivering azoniaspiro(3-alpha-benziloyloxy-nortropan-8,1'-pyrrolidine)-chloride over a 24-hour interval via an oral osmotic system confronts a fundamental solubility bottleneck. The drug’s aqueous solubility, measured at 48 mg/mL at 37°C in buffered media at pH 6.8, is sufficient for immediate release but imposes a volumetric expansion limit when the core is forced to imbibe water through a laser-drilled delivery orifice of 0.4 mm diameter on a cellulose acetate membrane. The formulation relies on a bilayer core geometry compressed on a high-speed bi-layer tablet press with a pre-compression force of 300 N and a main compression force of 4.5 kN. The active layer comprises 20 mg of the compound, polyethylene oxide WSR N-80 as the hydrophilic swellable polymer at a ratio of 1:3 (drug to polymer), and sodium chloride as an osmagent. The push layer employs polyethylene oxide WSR Coagulant with a molecular weight of 5 × 10⁶ Da, colored with red ferric oxide for visual identification of layer separation. Applying the ASTM D638-14 microtensile method to the cast film of the semi-permeable coating, plasticized with polyethylene glycol 3350 to achieve an elongation-at-break of 18%, ensures coat resilience under the internal osmotic pressure of 12 atm. The in-vitro release profile, validated per USP <724> Extended-Release testing, must follow zero-order kinetics with a 1.2 mg/hr delivery rate, a criterion threatened by incomplete membrane annealing if the coater’s inlet air temperature fluctuates by more than ±2°C during the 45-minute film formation sequence. This single-entity controlled-release tablet, encased in an osmotically active semi-permeable membrane, targets steady-state plasma concentrations without the peak-to-trough ratio that characterizes immediate-release forms of the muscarinic antagonist.

Press-coating offers an alternative strategy where the active-loaded inner core is surrounded by a barrier layer whose rate of erosion in intestinal fluid governs the lag time required for chronotherapeutic delivery. The inner core composition mimics the direct compression formula but uses a hardness specification of 70 N to 90 N because the subsequent over-compression during the press-coat step subjects the core to radial tensile stresses that can fracture it if it is too brittle. The outer coat consists primarily of high-viscosity hypromellose (Methocel K100M) at 65.0% w/w, lactose anhydrous at 28.0% w/w, and the active ingredient at only 7.0% w/w to create a characteristic bimodal release: an initial pulse from the outer shell, followed by a 4-hour erosion-mediated latent period, after which the inner core disintegrates rapidly. Published pharmacopoeial guidance, specifically Ph. Eur. 2.9.3 “Dissolution test for solid dosage forms,” governs the basket-over-disk method needed to constrain the buoyant pressed-coated tablet during dissolution runs in simulated intestinal fluid of pH 6.8 without enzyme.

Transitioning from solid dosage to sterile liquid manufacture, the presence of a quaternary ammonium structure in azoniaspiro(3-alpha-benziloyloxy-nortropan-8,1'-pyrrolidine)-chloride introduces a surface-active tendency that exacerbates protein adsorption and particulate generation when the substance is processed in glass-lined bioreactors or electropolished 316L stainless steel vessels. The compounding of a parenteral-grade solution for intravenous or intramuscular administration begins by dissolving the chloride salt in Water for Injection (WFI) at a concentration of 2.0 mg/mL, calculated as the free base, with the pH adjusted to 4.5–5.5 using dilute hydrochloric acid. The solution is then subjected to nitrogen sparging before terminal sterilization via autoclaving at 121°C for 15 minutes in a saturated steam cycle. During the holding phase, the ester bond situated at the alpha-benziloyloxy position becomes transiently labile; degradation follows a first-order model with a reaction rate constant k ≈ 0.0025 h⁻¹ at 121°C, yielding approximately 0.04% of a hydroxy-spiro impurity that must be tracked as a system suitability marker on a stability-indicating HPLC method validated per ICH Q2(R1). The terminal product is filled aseptically into 2 mL Type I borosilicate glass ampoules under a filtered nitrogen blanket, with the terminal sterilization step validated by a sterility assurance level (SAL) of 10⁻⁶ in accordance with ISO 11138-1:2017, and the particulate load controlled against USP <788> limits of NMT 6000 particles at ≥10 μm and NMT 600 particles at ≥25 μm per container. The ampoules constitute a finished injectable product intended for use in hospital settings where cholinergic blockade is clinically indicated.

Analytical profiling for release testing demands recognition that the azoniospiro nucleus, which spans the 8-azabicyclo[3.2.1]octane and pyrrolidine rings linked by a spiro carbon, is a strong UV chromophore exhibiting a λmax at 254 nm with a secondary shoulder near 262 nm. The pharmacopoeial HPLC method prescribes a reversed-phase C18 column (250 mm × 4.6 mm, 5 μm particle size) thermostated at 30°C, with a mobile phase consisting of a gradient mixture of phosphate buffer pH 2.8 and acetonitrile at a flow rate of 1.0 mL/min. The retention time of the parent peak is programmed to fall between 14.0 and 16.0 minutes under these conditions, with the resolution between the compound and its des-benziloyl analog required to be NLT 2.0. In line with ICH Q6A decision tree #2, degradation products that are identified as holding a structural alert for mutagenicity (such as a potentially formed epoxide on the benziloyl phenyl ring) are quantified against a TTC of 1.5 μg/day using a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method with electrospray ionization in positive ion mode, monitoring the MRM transition m/z 392.2 → 164.1 for the spiro-quaternary ammonium fragment. This testing battery, executed on a batch-to-batch basis, provides the supplier’s certificate of analysis and fulfills the exchange of regulatory starting materials under the International Council for Harmonisation’s Common Technical Document, Module 3.2.S.2, for the parenteral and oral antimuscarinic product family.